Subgen AI (MAGNA) Q3 2024 earnings summary

Executive summary

• Q3 2024 marked a transformative period with strengthened operational and business development capacities, including key management appointments and a strategic focus on the professional oral health market.

• Initiated a feasibility study with Salignostics and filed a patent for advanced magnetic test strip technology, aligning with the company's oral health strategy.

• Officially rebranded from Aegirbio AB to Magnasense AB to better reflect core assets and focus.

Financial highlights

• Total income for Q3 2024 was SEK 0M, down from SEK 0.2M in Q3 2023.

• Operating loss improved to SEK -10.3M from SEK -16.8M year-over-year; loss before tax was SEK -14.0M versus SEK -18.3M.

• Cash and cash equivalents at quarter-end were SEK 1.8M, down from SEK 23.4M a year earlier.

• Earnings per share improved to SEK -0.32 from SEK -0.61 year-over-year.

• Equity ratio at September 30, 2024, was -37%, compared to 12% in the prior year.

Outlook and guidance

• Continued focus on the professional oral health market, with ongoing development of market-driven solutions and prudent resource management.

• Ongoing efforts to expand product capabilities and advance solutions aligned with oral health market needs.